Lumos Secures Sixth US Medicare Reimbursement for FebriDx®
27 May 2025
Lumos has announced that it has received confirmation of Medicare reimbursement coverage for FebriDx from another Medicare Administrative Contractors (MACs), CGS Administrators, retroactive from 1 May 2025.
Lumos now has Medicare reimbursement from six of the seven MACs, representing over 85% of the total US Medicare payment coverage. Negotiations are ongoing with the remaining MAC.
Doug Ward, Managing Director of Lumos Diagnostics commented:
“Lumos remains committed to securing adoption from the remaining MAC, NGS, and pursuing reimbursement coverage from private payors, with the goal of achieving nationwide access for patients and supporting broad clinical adoption of FebriDx.”
Click to read the ASX release.
Lumos now has Medicare reimbursement from six of the seven MACs, representing over 85% of the total US Medicare payment coverage. Negotiations are ongoing with the remaining MAC.
Doug Ward, Managing Director of Lumos Diagnostics commented:
“Lumos remains committed to securing adoption from the remaining MAC, NGS, and pursuing reimbursement coverage from private payors, with the goal of achieving nationwide access for patients and supporting broad clinical adoption of FebriDx.”
Click to read the ASX release.
